STAB
Live / Registered — Registered (as of 28 Jul 2026)
What this means for you
Registered since 28 Jul 2026. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 79420148
- Registration number
- 8362484
- Mark type
- Stylized text
- Filed
- 27 Dec 2024
- Published for opposition
- 09 Jun 2026
- Registered
- 28 Jul 2026
- Attorney of record
- Bradley M. Stohry
Goods and services
- Class 005 — Pharmaceuticals: Biological preparations for use in cell cultures for medical purposes; preparations for detecting genetic predispositions for medical purposes; diagnostic reagents for medical use; chemical reagents for medical use; biological reagents for medical use; cells for medical use; living cells for medical use; antibodies for medical purposes; cell growth media for growing cells for medical or clinical use; cellular function activating agents for medical purposes; anti-cancer preparations; biopharmaceuticals for the treatment of cancer; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations and substances for the prevention of cancer; human and animal cells and related parts for medical use, namely, cell culture media for medical use, viral vectors, for medical use, namely, pharmaceutical preparations containing viral vectors for the treatment or prevention of cancer and immune-related diseases; chemical reagents for medical use, namely, lentiviruses, lentivirus particles and lentivirus plasmids, for medical use; therapeutic preparations and substances for gene and cell therapy for medical use, namely, pharmaceutical preparations for gene therapy and cell therapy for the treatment of cancer and immune-related diseases; gene therapy products, namely, genetically engineered tissues for transplant purposes; lentiviral vectors, for medical use, namely, pharmaceutical preparations containing lentiviral vectors for gene and cell therapy for the treatment of cancer and immune-related diseases; adeno-associated viral vectors, adenoviral vectors and non-viral vectors for the delivery of genes to cells for medical use, namely, pharmaceutical preparations for gene therapy for the treatment of cancer and immune-related diseases; pharmaceutical preparations for the treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention of diseases of the immune system; all the aforesaid goods expressly excluding substances and preparations for veterinary use; medicines and pharmaceuticals based on messenger RNA (mRNA) for the treatment of cancer and immune-related diseases; pharmaceutical and medicinal preparations for use in the field of targeting messenger RNA (mRNA) and triggering its degradation for the treatment of cancer and immune-related diseases; mRNA-based therapeutic preparations and therapeutic agents for the prevention and treatment in vivo, ex vivo and in situ of oncological diseases or tumors; pharmaceutical preparations consisting of messenger RNA and delivery agents comprised of lipid nanoparticle carriers and polymers for the delivery of mRNA to human cells for the treatment of cancer and immune-related diseases
- Class 042 — Scientific and technological services: Biological research; medical research services; scientific research in the field of genetics and genetic engineering; research and development in the pharmaceutical and biotechnology fields; gene therapy research; research and development in the field of microorganisms and cells; development of cell therapy products; product development in the field of immunotherapy; pharmaceutical drug development services in the field of cell therapy; pharmaceutical drug development services in the field of immunotherapy; development of gene-based medicines; design and development of medical technology in the field of cell therapy; design and development of medical technology in the field of immunotherapy; research and development of vaccines and medicines; consultancy relating to pharmaceutical research and development in the field of cell therapy; consultancy relating to pharmaceutical research and development in the field of immunotherapy; research and development services in the field of antibodies; research and development services in the field of gene expression systems; laboratory services relating to the production of monoclonal antibodies, namely, laboratory research services relating to pharmaceuticals and biotechnology; scientific services relating to the isolation and cultivation of human tissues and cells, namely, scientific research and scientific laboratory services; research and development services in the field of immunology; research and development services in the field of cell therapy; research and development services in the field of immunotherapy; research and development of mRNA drugs
- Class 045 — Legal and security services: Licensing authority services in the field of cellular therapy, namely, patent licensing, trademark licensing; licensing authority services in the field of immunotherapeutics, namely, patent licensing, trademark licensing; licensing of technology, namely, patent licensing, trademark licensing; licensing of intellectual property
Owner
Prosecution history
- 26 Aug 2026 — NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
- 26 Aug 2026 — NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
- 28 Jul 2026 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 28 Jul 2026 — REGISTERED-PRINCIPAL REGISTER
- 09 Jun 2026 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 09 Jun 2026 — PUBLISHED FOR OPPOSITION
- 03 Jun 2026 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 13 May 2026 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 13 May 2026 — EXAMINER'S AMENDMENT ENTERED
- 13 May 2026 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
- 13 May 2026 — EXAMINERS AMENDMENT E-MAILED
- 13 May 2026 — EXAMINERS AMENDMENT -WRITTEN
- 15 Mar 2026 — NOTIFICATION OF FINAL REFUSAL EMAILED
- 15 Mar 2026 — FINAL REFUSAL E-MAILED
- 15 Mar 2026 — FINAL REFUSAL WRITTEN